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Abstract
A recombinant C-terminus heavy chain fragment from botulinum neurotoxin serotype E (BoNT/E) is proposed as a vaccine
against the serotype E neurotoxin. This fragment, rBoNTE(Hc), was produced intracellular in Pichia pastoris GS115 by a three-step
fermentation process, i.e., glycerol batch phase and a glycerol fed-batch phase to achieve high cell densities, followed by a methanol
fed-batch induction phase. The rBoNTE(Hc) protein was puriWed from the soluble fraction of cell lysates using three ion-exchange
chromatography steps (SP Sepharose Fast Flow, Q Sepharose Fast Flow, Sp Sepharose High Performance) and polished with a
hydrophobic charge induction chromatography step (MEP HyperCel). Method development at the bench scale was achieved using 7–
380 mL columns and the process was performed at the pilot scale using 0.5–3.1 L columns in preparation for technology transfer to
cGMP manufacturing. The puriWcation process resulted in greater than 98% pure rBoNTE(Hc) based on HPLC and yielded up to
1.01 g of rBoNTE(Hc)/kg cells at the bench scale and 580 mg vaccine/kg cells at the pilot scale. N-terminal sequencing showed that the
puriWed rBoNTE(Hc) N-terminus is intact and was found to protect mice against a challenge of 1000 mouse intraperitoneal LD50’s of
BoNT/E.
This article is a U.S. government work, and is not subject to copyright in the United States.
 2005 Elsevier Inc. All rights reserved.
Keywords: Botulinum; Pichia pastoris; Ion-exchange chromatography; Hydrophobic charge induction chromatography; Homogenized; Filtration;
Recombinant protein; Scale-up

Botulinum neurotoxin, a National Institute of Allergen
and Infectious Disease class A agent, has been weaponized [1]. There is a need for a safe, well characterized, and
eYcacious recombinant vaccine that will protect against
all seven known serotypes of the toxin. Such a product is
needed to protect US military personnel, Wrst-responders
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in the civilian environment, and, if necessary, civilians
who may be at risk because of their geographical locations in the United States. Clostridium botulinum produces
seven antigenically distinct neurotoxins diVerentiated
serologically by speciWc neutralization [2]. These have
been designated as serotypes A through G and are the
most toxic substances known [3]. Thus, seven monovalent
vaccines are required if full immunologic protection
against botulinum neurotoxins is to be achieved. The botulinum toxin is expressed as a single, 150-kDa polypeptide
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chain that is posttranslationally nicked, forming a simple
two-chain polypeptide that consists of a C-terminal 100kDa heavy chain joined by a single disulWde bond to the
50-kDa light chain [4]. The toxin has three distinct
regions: a translocation domain, a binding domain, and a
catalytic domain. The carboxy terminus of the heavy
chain binds to a nerve cell receptor at the neuromuscular
junction [5] and the amino terminus of the heavy chain is
capable of forming channels in the cell membrane, allowing internalization of the toxin [6,7]. Finally, the toxin’s
light chain, a Zn2+-containing endoprotease, is released
into the cell cytoplasm, cleaving a speciWc synaptic protein involved in the docking of acetylcholine-containing
vesicles from binding to the synaptic membrane. This
blocking prevents the vesicles from releasing acetylcholine
into the synapse at the neuromuscular junction, resulting
in Xaccid muscle paralysis [8]. In humans, botulism is
characterized by a descending Xaccid paralysis, starting in
the head region and descends to the muscles controlling
breathing.
The Hc fragments of BoNT (A–F) were shown to be
non-toxic, antigenic [9], and capable of eliciting a protective immunity in animals challenged with homologous
BoNT [10,11]. These results prompted an eVort to
develop a recombinant botulinum vaccine against all
seven serotypes using the Hc fragments as vaccine antigens [4,12–17]. As mentioned earlier, the seven serotypes
are distinct antigenitically, requiring the vaccine to be
comprised of seven distinct antigens. To add to the complexity, the heavy chain fragments for each of the seven
serotypes are distinct proteins with variable degrees of
homology. By way of illustration, the isoelectric point of
the recombinant fragments calculated from the known
sequences are as follows: serotype A: 9.3, B: 7.1, C: 5.6, D:
6.0, E: 8.3, F: 9.1, G: 7.9, underscoring the fact that fermentation and puriWcation of each antigen will be
unique. It was the hope back in 1994 when the The University of Nebraska-Lincoln Biological Process Development Facility (BPDF) began working with Dr. Leonard
Smith of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) on this project
that once a fermentation and puriWcation process was
developed for BoNTB(Hc) [13] that all subsequent serotypes would follow suite. This was found not to be the
case for BoNTA(Hc) [14] and continues to be the case for
each of the serotypes we have worked on. The experiences we learned from previous puriWcation research are
applied to the next serotype, but the amount expressed
during fermentation, the methods of puriWcation, and the
characteristics of the molecules are diVerent for each
serotype. There in lies the challenge of a recombinant
botulinum vaccine, seven diVerent processes to produce
seven diVerent proteins, with all seven distinct Hc fragments formulated into one vial.
This paper describes research, development, and scaleup of a process to produce a recombinant botulinum neurotoxin serotype E, heavy chain C-terminal fragment

(rBoNTE(Hc))1 candidate vaccine suitable for transfer to a
current good manufacturing practice (cGMP) facility for
production of clinical material. The rBoNTE(Hc) fragment
is expressed intracellularly in Pichia pastoris using a threephase high-cell density fermentation incorporating a 9 h
methanol induction to minimize proteolytic degradation of
the rBoNTE(Hc). Initial process development was performed at the bench scale resulting in a four-step process
and concluded with four bench-scale demonstration runs to
determine process reproducibility. Two pilot-scale runs
were performed to demonstrate the scalability of this process for continuation towards the goal of cGMP manufacturing.
Materials and methods
Molecular biology
rBoNTE(Hc) gene was originally obtained from C. botulinum NCTC 11219. At the Division of Toxicology and
Aerobiology of USAMRIID, rBoNTE(Hc) codon optimized gene was inserted into pHILD4 expression vector at
EcoRI site. After transformation into P. pastoris GS115
(his4), cells were screened with increasing amount of Genticin (G418) to determine a multi-copy expression vector.
The multi-copy clone developed at USMRIID was then
tested for viability and restriction map of the insert by
Southern blot.
Fermentation
Pichia pastoris GS115 harboring three copies of the
rBoNTE(Hc) encoding gene with expression under the control of AOX1 promoter was grown to high cell density on
deWned medium. The fermentation was carried out in three
diVerent phases, i.e., glycerol batch phase, glycerol fedbatch phase, and the methanol fed-batch phase. Fermentations were performed in 5 L fermentor (BioXo 3000, New
Brunswick ScientiWc Edison, NJ) or in 19 L fermentor
(NLF, Bioengineering AG, Sagenrainstrasse 7 CH-8636
Wald, Switzerland) at pH 5.0 and 30 °C. The cells were
grown to desired cell density on glycerol and then induced
on methanol for expression as previously described

1
Abbreviations used: BCA, bicinchoninic acid; rBoNT, recombinant
botulinum neurotoxin; rBoNTE(Hc), recombinant botulinum neurotoxin
serotype E, heavy chain C-terminal fragment; BSA, bovine serum albumin; CV, column volume; FF, fast Xow; HP, high performance; Hc, heavy
chain C-terminal fragment; kDa, kilo Dalton; MW, molecular weight;
PVDF, polyvinylidene diXuoride; Q, quaternary amine; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; SP, sulfopropyl;
HCIC, hydrophobic charge induction chromatography; WCW, wet cell
weight; TBS, Tris base-buVered saline; PMSF, phenylmethylsulfonyl Xuoride; IEC, ion-exchange chromatography; cGMP, current good manufacturing practices; SEC, size exclusion chromatography; SCX, strong cation
exchange chromatography; HIC, hydrophobic induction chromatography; PDS, puriWed drug substance; NaCl, sodium chloride; i.p., intraperitoneal.
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[13,14,17]. The cells were grown exponentially on methanol
containing 12 mL/L of PTM1 salts [18] and induced for 9 h.
Samples were withdrawn for analyses to determine the wet
cell weight and rBoNTE(Hc) production.
Bench-scale cell harvest and disruption
Cells were harvested by centrifugation at 11,300g at 4 °C
for 30 min using a Sorvall Evolution RC Centrifuge (Kendro Laboratory Products, Asheville, NC). Cell paste was
either frozen at ¡80 °C or processed immediately. Two
hundred grams of cell paste was suspended in 50 mM
sodium phosphate mono basic, 10 mM sodium chloride
(NaCl), and pH 7.4, to 20% (w/v) solids to wash the fermentation medium away. The suspension was centrifuged at
11,300g at 4 °C for 15 min. Cell paste was resuspended in
50 mM sodium phosphate mono basic, 10 mM NaCl, pH
7.4 to 20% (w/v) solids and homogenized using a MicroXuidizer M-110EH (MicroXuidics, Newton, CA) set at
22,000 psi with the lysate chilled to <10 °C before processing. Two passes were performed to obtain at least 85% cell
disruption determined with a hemocytometer. The homogenate was clariWed at 11,300g for 30 min at 4 °C followed by
Wltration through a Pall AcroPak 200 with a 0.2 m Fluorodyne II membrane (Pall, East Hills, NY) and loaded immediately onto the Wrst column.
Bench-scale puriWcation
All bench-scale chromatographic separations were performed on a BioCad Workstation (Applied Biosystems,
Foster City, CA) at room temperature, with the load material placed on ice. A 5.0 cm £ 19.5 cm column (Waters Chromatography, Milford, MA) packed with 383 mL of strong
cation exchange SP Sepharose Fast Flow resin (Amersham
Biosciences Piscataway, NJ) was equilibrated with 5 column volumes (CV) of 50 mM sodium phosphate mono
basic, 10 mM NaCl, pH 7.4. Supernatant was loaded onto
the column at a linear velocity of 300 cm/h followed by a 10
CV wash with the equilibration buVer. The product was
eluted using a 5 CV step of 50 mM sodium phosphate mono
basic and 100 mM NaCl, pH 7.4.
The SP Sepharose FF product was loaded directly onto
a 2.7 cm £ 19.8 cm column (Applied Biosystems, Foster
City, CA) packed with 113 mL strong anion exchange Q
Sepharose Fast Flow resin (Amersham Biosciences Piscataway, NJ). The column was equilibrated with 5 CV of
50 mM sodium phosphate mono basic, pH 7.4 at a linear
velocity of 300 cm/h. The Xow through fraction was collected from the Q Sepharose FF column as the
rBoNTE(Hc) does not bind and passes through the column.
The Q Sepharose FF product was diluted with an equal
volume of 25 mM succinate, pH 4.0 to bring down the pH
to approximately pH 6.0. The diluted product was loaded
onto a 2.7 cm £ 13.1 cm (Applied Biosystems, Foster City,
CA) 75 mL strong cation exchange SP Sepharose HP resin
(Amersham Biosciences Piscataway, NJ) that was pre-
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Table 1
Bench-scale puriWcation of rBoNTE(Hc)a
Step

Volume
(mL)

Lysate
SP Sepharose FF
Q Sepharose FF
SP Sepharose HP
HCIC
DiaWltration

1300 § 130
800 § 100
1400 § 480
370 § 120
275 § 72
504 § 123

Protein concentration
(mg/mL)
16 § 3
0.9 § 0.2
0.40 § 0.15
0.65 § 0.17
0.60 § 0.12
0.30 § 0.02

Total protein
(mg)
21,000 § 4100
700 § 150
520 § 130
230 § 48
163 § 45
153 § 42

a
Average of four bench-scale puriWcation runs starting from 200 g cells
wet weight.

equilibrated with 5 CV of 25 mM succinate, pH 6.0 at
200 cm/h. After loading, the column was washed with 5 CV
of 25 mM succinate, 200 mM NaCl, pH 5.0 buVer. The
rBoNTE(Hc) was eluted from the column using a 25 CV
linear gradient from 25 mM succinate, 200 mM NaCl, pH
5.0 to 25 mM succinate, 300 mM NaCl, pH 5.0.
The SP Sepharose HP product was diluted with an
equal volume of 50 mM sodium phosphate mono basic,
pH 7.4 to adjust the pH up to 6.0. The diluted product was
loaded onto a 2.7 cm £ 13.6 cm (Applied Biosystems, Foster City, CA) 77 mL hydrophobic charge induction chromatography column, BioSepra MEP HyperCel resin
(Ciphergen, Fremont, CA) and equilibrated with 5 CV of
25 mM succinate, pH 6.0 at 300 cm/h. After loading, the
column was washed with 5 CV of 25 mM succinate, pH 5.0
buVer. rBoNTE(Hc) was eluted from the column using a
15 CV linear gradient from 25 mM succinate, pH 5.0 to
25 mM succinate, pH 4.0.
The Wnal product was dia-Wltered with 15 mM succinate
pH 4.0 using Millipore Pellicon XL Filter, with a 50 cm2
10K regenerated cellulose membrane (Millipore, Bedford,
MA) until the Wnal product reached a pH of 4.0. The puriWed drug substance was sterile Wltered with an AcroPak 20,
with a 0.2 m Fluorodyne II membrane (Pall, East Hills,
NY) and stored at 2–8 °C (Table 1).
Pilot-scale cell harvest and disruption
Cells harvested from a 19 L fermentation were centrifuged at 11,300g at 4 °C for 30 min using a Sorvall Evolution RC Centrifuge (Kendro Laboratory Products,
Asheville, NC) and processed immediately. Thousand three
hundred to thousand Wve hundred grams of cell paste were
suspended in 50 mM sodium phosphate mono basic, 10 mM
NaCl, pH 7.4 to 20% (w/v) solids to remove fermentation
medium. The suspension was centrifuged at 11,300g for
15 min and resuspended in 50 mM sodium phosphate mono
basic, 10 mM NaCl, pH 7.4 to 20% (w/v) solids. Cells were
homogenized using a MicroXuidizer M-110EH (MicroXuidics, Newton, CA) set at 22,000 psi. Two passes were performed to obtain at least 85% cell disruption determined
with a hemocytometer. The homogenate was centrifuged at
11,300g for 30 min at 4 °C and Wltered through a Pall 0.2 m
Fluorodyne II membrane (Pall, East Hills, NY) prior to
loading onto the Wrst column.
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Pilot-scale puriWcation
All chromatographic separations were performed using a
North Carolina SRT (Cary, NC) pilot-scale chromatography
skid. All chromatographic conditions were the same as the
bench-scale work, i.e., linear velocities, equilibration, washing, and elution methods. The SP Sepharose FF step was performed using a 3.14 L (20 cm £ 10 cm) BPG 200/500 column
(Amersham Pharmacia Biotech, Piscataway, NJ). The Q
Sepharose FF step was performed on a 1.02 L (10 cm £
13 cm) BPG 100/500 column (Amersham Biosciences Piscataway, NJ). The SP Sepharose HP step was performed using a
557 mL (7 cm £ 10 cm) QS 70/500 column (Millipore, Bedford, MA), and the BioSepra MEP HyperCel step was performed using a 531 mL (6 cm £ 18.8 cm) Vantage 60A
column (Millipore, Bedford, MA). Final product was diaWltered to pH 4.0 using 15 mM succinate, pH 4.0 at 5 °C with
a North Carolina SRT Optisep 3000 bench Wltration unit
equipped with two 2 ft2 of 10 kDa regenerated cellulose, part
number 52-D5B-0010 (North Carolina SRT Cary, NC).
Final product was sterile Wltered with an AcroPak 20, with a
0.2 m Fluorodyne II membrane (Pall, East Hills, NY) and
stored at 2–8 °C (Table 2).
Protein analysis
Total protein concentrations were determined using
the BCA (Pierce Chemical, St. Louis, MO) standard assay,

using BSA as a standard. Purity was determined by SDS–
PAGE using 10% Bis–Tris gels with Mops buVer system
(Novex, San Diego, CA) stained with Coomassie blue.
Western blot analysis was performed using polyclonal
chicken anti-rBoNTE(Hc) antibody incubated at 0.33 g/
mL for 1 h at room temperature. The secondary antibody
was a peroxidase labeled aYnity-puriWed goat antichicken IgG (Kirkegaard & Perry Laboratories,
Gainsburg, MD) incubated at 0.15 g/mL for 1 h at room
temperature. The SDS–PAGE-separated proteins were
transferred to PVDF membranes (Bio-Rad, Hercules,
CA) at 25 V for 20 min, blocked with 5% non-fat dried
milk for 30 min and washed with Tris base-buVered saline
(TBS) prior to treatment with antibodies. Blots were then
visualized by chemiluminescence using the ELC plus
Detection Kit (Amersham Pharmacia Biotech, Piscataway, NJ). Protease detection was performed with an EnzChek Protease Assay Kit (Molecular Probes, Eugene,
OR) with Bodipy FL Casein as the substrate. N-terminal
sequencing was performed by the University of NebraskaMedical Center Protein Core Facility using a ABI Procise
494 Sequencer (Applied Biosystems, Foster City, CA)
(Table 3). The Biological Process Development Facility
(BPDF) Quality Control Laboratory estimated purity
and quantity of rBoNTE(Hc) by HPLC using strong cation exchange chromatography (SCX). SCX analysis was
performed with a 50 mm length PolyLC Polysulfoethyl A
column (PolyLC, Columbia, USA). For sample analysis a

Table 2
Second pilot-scale puriWcation of rBoNTE(Hc)a
Step

Volume (mL)

Protein concentration
(mg/mL)

Total protein
(mg)

Estimated purityb
(%)

rBoNTE(Hc)c (mg)

Step yield
(%)

Total yield
(%)

Lysate
SP Sepharose FF
Q Sepharose FF
SP Sepharose HP
HCIC
DiaWltration

7,500
12,800
12,500
3,750
2,400
2,720

14
0.32
0.22
0.33
0.33
0.27

105,000
4045
2700
1253
780
734

3
70
80
92
99
99

3150
2831
2160
1152
772
727

100
90
76
53
67
94

100
90
69
37
25
23

a
b
c

PuriWcation is from 1.3 kg cells wet weight.
Purity estimated by SCX-HPLC.
Determined by multiplication of total protein and purity.

Table 3
N-terminal sequence of puriWed rBoNTE(Hc)
Sample

N-terminal sequence

Intact rBoNTE(Hc)

pI of protein: 8.8
Protein MW: 52220
Amino acid composition: A9 C4 D29 E14 F21 G21 H6 I44 K34 L32 M7 N71 P6 Q12 R15 S37 T26 V24 W8 Y29
MGESQQELNSMVTDTLNNSIPFKLSSYTDDKILISYFNKFFKRIKSSSVLNMRYKNDKYVDTSGYDSNININ
GDVYKYPTNKNQFGIYNDKLSEVNISQNDYIIYDNKYKNFSISFWVRIPNYDNKIVNVNNEYTIINCMRDNN
SGWKVSLNHNEIIWTLQDNAGINQKLAFNYGNANGISDYINKWIFVTITNDRLGDSKLYINGNLIDQKSILN
LGNIHVSDNILFKIVNCSYTRYIGIRYFNIFDKELDETEIQTLYSNEPNTNILKDFWGNYLLYDKEYYLLNV
LKPNNFIDRRKDSTLSINNIRSTILLANRLYSGIKVKIQRVNNSSTNDNLVRKNDQVYINFVASKTHLFPLY
ADTATTNKEKTIKISSSGNRFNQVVVMNSVGNNCTMNFKNNNGNNIGLLGFKADTVVASTWYYTHMRDHTNSNGCFWN
FISEEHGWQEK

Bench-scale rBoNTE(Hc)-ND-DP-010
Pilot-scale ND(E)-ER-001
Pilot-scale ND(E)-ER-002

GESQQ
GESQQ
GESQQ
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1 mL/min gradient elution from 65% mobile phase A
(20 mM Tris at a pH 7.7) and 35% mobile phase B (20 mM
Tris, 2 M NaCl at a pH 7.7) to 60% mobile phase A and
40% mobile phase B, over 6 min.
Mouse potency bioassay
The potency of puriWed rBoNTE(Hc) was determined
using a mouse potency bioassay [19,20]. Groups of 10
female mice (stain Crl:CD-1 (Charles River, NC)) were
intramuscularly vaccinated twice with threefold dilutions
of antigen (8.1, 2.7, 0.9, 0.3, 0.1, 0.033, and 0.011 g
rBoNTE(Hc)/mouse). The antigen was formulated in
25 mM succinate, 15 mM phosphate, pH 5.0, and diluted
into Wnal concentrations of 0.2% Alhydrogel (HCI Biosector, Frederikssund, Denmark), 5% mannitol, 0.9% NaCl,
pH 5.5. Vaccinations were at 2-week intervals, and the
mice were challenged 3 weeks after the Wnal vaccination
with 1000 mouse i.p., LD50 BoNT/E toxin complex. Mice
were observed twice daily for 5 days post challenge.
Results were tabulated and analyzed using probit analysis
(SPSS, Chicago, IL).
Results and discussion
Fermentation
It was determined that after 9 h of methanol induction
the amount of rBoNTE(Hc)/unit cell did not increase and
that intracellular protease levels increased by nearly 50% as
the induction time increased to 26 h. P. pastoris GS115
rBoNTE(Hc) induced on methanol for 26 h produced
increased level of proteases that were detrimental to the stability of rBoNTE(Hc) during the puriWcation process and
under Wnal product storage conditions. The 9 h induction
time was chosen.
Bench-scale puriWcation
Initial cell disruption experiments consisted of four
passes through the MicroXuidizer as described in Material and methods section. It was found by bicinchoninic
acid (BCA), Western blot assays, and the hemocytometer, that after two passes the protein concentration and
the intensity of Western blot bands on subsequent passes
were the same. Two passes were also advantageous since
this reduced the total processing time of the homogenization step, reducing the potential for proteolytic degradation of rBoNTE(Hc). If homogenate was stored at 2–8 °C
for 24 h, the rBoNTE(Hc) would degrade to multiple
fragments based on Western blot. The length of the methanol induction had an impact on the quality of the
product as mentioned above. Initially, 2 mM phenylmethylsulfonyl Xuoride (PMSF) was added to the cell suspension just prior to disruption to inhibit protease activity
and prevent the formation of degradation products.
From a cGMP perspective, PMSF is not desirable, and
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should be removed prior to scale-up. Adding 10 mM
NaCl to the breaking buVer reduced the binding of proteases to the SP Sepharose Fast Flow resin during the capture step and optimizing chromatography conditions
resulted in additional protease activity eluting during the
wash step (Fig. 1). A combination of 9 h methanol induction time, a short processing time for harvested cells, and
optimization of the separation of proteases from the
rBoNTE(Hc) during the capture step eliminated the need
for PMSF in the homogenization buVer.
The rBoNTE(Hc) was puriWed at the bench scale using
ion-exchange and hydrophobic charge induction chromatography techniques. Batch binding studies evaluated both
anion and cation exchange resins over a pH range from 4 to
8 for capture of rBoNTE(Hc). ClariWed cell lysate at a protein/resin ratio of 5 mg/mL was incubated at 4 °C for 3 h.
Optimum binding was based on the least amount of
rBoNTE(Hc) present in the supernatant. Batch and dynamic
binding were compared at a total protein load of 20 mg/mL
of resin followed by a step elution using 300 mM NaCl. Surprisingly, 78.2 mg/g total protein of rBoNTE(Hc) was recovered from dynamic binding to the capture column, while
only 33.9 mg rBoNTE(Hc)/g of total protein was recovered
from batch binding. This was over a twofold increase in the
amount of rBoNTE(Hc) recovered from the Wrst step.
Initial elution of the rBoNTE(Hc) from the SP
Sepharose FF column was achieved using a 300 mM NaCl
step elution in 50 mM sodium phosphate buVer at pH 7.4.
Further optimization determined that rBoNTE(Hc) eluted
oV at 100 mM NaCl. This decreased the amount of contaminants and eliminated a major contaminant at the same
MW as the rBoNTE(Hc) (Fig. 2). The maximum total protein loaded onto the SP Sepharose FF column was 55 mg/
mL resin.
Product from the capture column was negatively puriWed through a Q Sepharose FF column removing a majority of the larger molecular weight Pichia proteins that are
present after the capture step (Fig. 3). Analysis of the eluted
contaminants by Western blot found that rBoNTE(Hc) was
not present at a protein load of 5.5 mg/mL resin at the
bench scale. This protein load was used for future processing runs and scale-up.
The Xow through from the Q Sepharose FF column was
loaded directly onto a SP Sepharose HP resin. Initially a
Source 15 S resin was used for this step, but due to scalability problems and the cost of this resin, a resin screen was
performed using Poros 50 HS, SP Sepharose HP, CM
650 M, Source 30 S, and Fractrogel EMD. Based on the
results of the resin screen and factoring in cost, SP
Sepharose HP resin was selected. The SP Sepharose HP
resin increased the purity of rBoNTE(Hc) to 92% based on
strong cation exchange (SCX)-HPLC. The elution gradient
was optimized from a 45 CV gradient of 100–400 mM NaCl
in 25 mM succinate, pH 5.0 to a 25 CV gradient of 200–
300 mM NaCl in 25 mM succinate, pH 5.0.
Hydrophobic charge induction chromatography (HCIC)
was used as a polishing step to remove a degradation

364

M.P. Dux et al. / Protein Expression and PuriWcation 45 (2006) 359–367

Fig. 1. Protease detection during the capture of rBoNTE(Hc). A chromatogram of the capture step for a bench-scale puriWcation of rBoNTE(Hc) with no
PMSF in the cell lysate shown with the corresponding speciWc activity’s of proteases in each of the fractions taken during the separation with bodipy
casein used as the substrate.

Fig. 2. Capture step optimization. Coomassie-stained SDS–PAGE and Western blot of fractions taken across the elution peaks of the SP Sepharose FF
capture step, used for determining the optimal NaCl step elution.

product of rBoNTE(Hc) (Fig. 4 and Table 4). A total protein load of 3.5 mg/mL resin resulted in no rBoNTE(Hc)
detected in the Xow through. By collecting only the back
half of the elution peak (Fig. 4) it was possible to separate

the degraded rBoNTE(Hc) from the intact rBoNTE(Hc),
the degraded rBoNTE(Hc) comes from the omission of
PMSF in the lysis buVer. The puriWed drug substance
(PDS) was shown to be a single band on SDS–PAGE

M.P. Dux et al. / Protein Expression and PuriWcation 45 (2006) 359–367
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Table 4
HPLC-SCX of HCIC fractions

Fig. 3. SDS–PAGE of chromatography products. SDS–PAGE of the
diVerent product peaks from all the chromatography steps in the
rBoNTE(Hc) puriWcation process with an equal total protein load across
the gel. Lane 1, See Blue Plus 2 MW Marker; lane 2, cell lysate; lane 3, Sp
Sepharose FF product; lane 4, Q Sepharose FF product; lane 5, SP
Sepharose HP product; and lane 6, HCIC product.

Sample ID

Retention time

HCIC load
HCIC fraction 1
HCIC fraction 2
HCIC fraction 3
HCIC fraction 4
HCIC fraction 5

8.78
8.88
8.83
8.79
8.77
8.76

Area of intact rBoNTE(Hc) (%)
90.16
86.62
90.31
96.14
100.00

(Figs. 3 and 4) and >98% by SCX-HPLC (Table 4). The pH
of the PDS as it eluted from the HCIC column is approximately pH 4.7. By SDS–PAGE, it has been demonstrated
that the PDS will degrade over a 4 day period at 4 °C if the
pH of the PDS is above a pH 4.7. However, the protein has
been shown to be stable over the same storage period at
4 °C following reduction of the pH to pH 4.0 prior to storage (Figs. 5 and 6). The entire puriWcation process from
harvesting to Wnal sterile-Wltering at the bench scale was
performed with in 10 h.
Four bench-scale puriWcation runs were performed to
determine the robustness of the process. The PDS from
these runs were very similar in purity and elution proWles.

Fig. 4. HCIC chromatogram and SDS–PAGE. Chromatogram and SDS–PAGE of the HCIC column step showing how the degradation product is
remove across the elution of the rBoNTE(Hc) peak. Lane 1, See Blue plus 2 MW Marker; lane 2, HCIC load; lane 3, HCIC fraction 1; lane 4, HCIC fraction 2; lane 5, HCIC fraction 3; lane 6, HCIC fraction 4; and lane 7, HCIC fraction 5.
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Pilot-scale puriWcation

Fig. 5. Stability of rBoNTE(Hc) at pH 5.0. The stability of rBoNTE(Hc) in
a pH 5.0 buVer stored at 4 °C for 4 days shown by SDS–PAGE. Lane 1,
See Blue plus 2 MW Marker; lane 2, rBoNTE(Hc)-DP-007 Day 0; lane 3,
rBoNTE(Hc)-DP-007 Day 1; lane 4, rBoNTE(Hc)-DP-007 Day 2; lane 5,
rBoNTE(Hc)-DP-007 Day 3; and lane 6, rBoNTE(Hc)-DP-007 Day 4.

Two 19 L fermentations and two pilot-scale puriWcations
runs were performed. These fermentations resulted in Wnal
wet cell weights of 175 and 139 g/L with Wnal volumes of
10.2 and 11.8 L, respectively.
The Wrst pilot-scale puriWcation was performed using
freshly harvested cell mass and produced 462 mg PDS/kg
cell mass. Upon completion of the run, analysis showed the
Wnal product to contain a minor, lower molecular weight
form of rBoNTE(Hc) by SDS–PAGE and was 97% pure by
SCX-HPLC. This contaminant was due to fraction selection during the HCIC column step. N-terminal sequencing
determined the PDS had an intact N-terminus (Table 2).
A second pilot-scale puriWcation generated a 100% pure
product based on SCX-HPLC and no lower molecular
weight form of rBoNTE(Hc) was seen by SDS–PAGE. The
second pilot-scale run also produced a higher over all yield
(Table 3). The product was collected from the HCIC chromatography step just before the apex of the peak, consistent with the bench-scale runs. The HPLC analysis
indicated (data not shown) that the lower molecular weight
contaminant elutes from the column at the beginning of the
peak and the pure rBoNTE(Hc) elutes at the end of the
peak. A residual DNA test was performed on the Wnal
product (AppTec, Philadelphia, PA) and was below the
limit of detection (<5 pg DNA/100 g of rBoNTE(Hc)). Nterminal sequencing determined the PDS had an intact Nterminus (Table 2).
Mouse potency assay
A mouse bioassay was used to determine rBoNTE(Hc)
vaccine potency. Material from the second production runs
was used for vaccinations. Potency assay results (Fig. 7)
showed protection to be centered, with an ED50 (eVective
dose protecting half the mice) of 190 ng, having 95% conWdence limits of 38–678 ng. The potency of this rBoNTE(Hc)

Fig. 6. Stability of rBoNTE(Hc) at pH 4.0. The stability of rBoNTE(Hc) in
a pH 4.0 buVer stored at 4 °C for 4 days shown by SDS–PAGE. Lane 1,
See Blue plus 2 MW Marker; lane 2, rBoNTE(Hc)-DP-007 Day 0; lane 3,
rBoNTE(Hc)-DP-007 Day 1; lane 4, rBoNTE(Hc)-DP-007 Day 2; lane 5,
rBoNTE(Hc)-DP-007 Day 3; lane 6, and rBoNTE(Hc)-DP-007 Day 4.

The yields ranged from 577 mg of puriWed rBoNTE(Hc)/
kg cell mass to 1 g of puriWed rBoNTE(Hc)/kg cell mass
(Table 1), and yield varied based on the cut on the Wnal
HCIC column. Analysis by N-terminal sequencing
showed the rBoNTE(Hc) to have an intact N-terminus
(Table 2).

Fig. 7. Potency plot. Plot of the number of surviving mice vs. the microgram dosage of rBoNTE(Hc).
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preparation is roughly equivalent to potencies of other
rBoNT vaccines, which range from 89 to 116 ng [19].
Conclusion
The production and puriWcation of recombinant heavy
chain fragment C of botulinum neurotoxin serotype E from
P. pastoris GS115 using the process described above has
been scaled-up and resulted in similar product purity at
both the bench and pilot scales. The rBoNTE(Hc) was most
stable stored at a pH of 4.0 in 15 mM succinate. During the
HCIC puriWcation step, in the future it is recommended
that SCX-HPLC should be used as an in-process assay to
adequately determine the proper fraction selection, to avoid
including the lower molecular contaminant in the PDS.
During these studies our objective was to use peak shape to
determine fraction selection. Though this works, to optimize yield, in-process analysis is recommended. The puriWcation process required four chromatographic steps with
no ultraWltration steps between each chromatography step.
The formulation step required a membrane diaWltration.
The product was intact and comparable in potency to other
rBoNT vaccines.
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